Chugai Pharmaceutical Co., Ltd. · TSE:4519
Chugai Pharmaceutical — Q3 2010 Earnings Presentation
17 slides from Chugai Pharmaceutical's earnings presentation, Oct 22, 2010
Slide 1: FY2010 3Q Financial Overview
FY2010 3Q Financial Overview CHUGAI PHARMACEUTICAL CO., LTD. Executive Vice President and CFO Ryuzo Kodama O t b 22, October 22 2010
Slide 2: Forward-Looking Statements
FY2010 3Q Financial Overview F Forward-Looking d L ki St Statements t t This presentation may include forward-looking statements pertaining to the business and prospects of Chugai Pharmaceutical Co., Ltd. (the “Company”). These statements reflect fl t the th Company’s C ’ currentt analysis l i off e
Slide 3: Summary
FY2010 3Q Financial Overview Summary Solid growth continued in Sales excluding Tamiflu • Sales excl. Tamiflu: +9.8 billion JPY (+4.0%) Domestic +3.3％, Overseas +10.1% • Sales of Tamiflu: -40.0 billion JPY • Other Operating Revenues: -3.5 3 5 billion JPY • Total Revenues: -33.6 billion JPY (-10.8%)
Slide 4: Financial Overview Jan-Sep
Year on Year FY2010 3Q Financial Overview Financial Overview Jan Jan-Sep Sep 2009 2010 (Billion JPY) (Billion JPY) Variance Jan-Sep Revenues Jan-Sep Revenues As % of As % of % Sales excl. Tamiflu +9.8 Revenues 309.7 276.1 -33.6 -10.8 Sales of Tamiflu* -40.0 Sales 303.4 273.3 -30.1 -9.9 Other O
Slide 5: Sales excluding Tamiflu Jan-Sep
Year on Year FY2010 3Q Financial Overview Sales excluding Tamiflu Jan-Sep Jan Sep (Billion JPY) Sales excl. Tamiflu 257.4 (+9.8, +4.0%) ▲ 10 0 0 10 247 6 247.6 Overseas +2.4, +10.1% 26.1 -3.7 Herceptin Avastin 23.7 (18.3) (36.8) +12.5 Others Actemra 27.111.7% Epogin 30.1 -3.0, -10.0% -3.1 ((29.2)) (
Slide 6: Tamiflu Sales Performance
FY2010 3Q Financial Overview Tamiflu Sales Performance Fiscal Term Sales * (Billion JPY) FY2005 12 FY2005.12 FY2006 12 FY2006.12 FY2007 12 FY2007.12 FY2008 12 FY2008.12 FY2009 12 FY2009.12 FY2010 12 FY2010.12 C a se s p e r Seasonall S se n ti n e l * Jan-Jun Jul-Dec Jan-Jun Jul-Dec Jan-Jun Jul-Dec
Slide 7: Operating Income Jan-Sep
Year on Year FY2010 3Q Financial Overview Operating Income Jan-Sep Jan Sep 2009 2010 (Billion JPY) Variance (Billion JPY) Jan-Sep Jan-Sep (%) Gross Profit Revenues 309.7 276.1 -33.6 -10.8 from Sales Cost of Sales 143.3 119.6 -23.7 -16.5 Other Operating Gross Profit 166.4 156.5 -9.9 -5.9 -6.5 Revenue
Slide 8: Financial Overview Jul-Sep
Year on Year FY2010 3Q Financial Overview Financial Overview Jul-Sep Jul Sep 2009 2010 (Billion JPY) (Billion JPY) Variance Jul-Sep As % of Revenues Jul-Sep As % of Revenues % Revenues 118.0 93.7 -24.3 -20.6 Sales excl. Tamiflu +1.8 Sales 117 5 117.5 92 6 92.6 -24 9 -24.9 -21 2 -21.2 Avastin +4.6
Slide 9: Revision of Forecast: Overview
Revision of Forecast FY2010 3Q Financial Overview Overview Actual Original Forecast Feb 3 Revised Forecast Oct 22 2009 Jan-Sep (Billion JPY) 2010 2010 Revision 2010 /Jan-Dec Jan-Sep Jan-Dec Prog. Jan-Dec Prog. (%) (%) (%) Revenues 276.1 418.5 66.0 -22.7 395.8 69.8 72.2 Sales 273.3 414.0 66.0 -23.2 3
Slide 10: Revision of Sales Forecast
Revision of Forecast FY2010 3Q Financial Overview Revision of Sales Forecast Original Revised * Actual Forec ast Billion J PY Forecast Prog. Rev is ion Forecast Prog. Jan-Sep Oct-Dec Jan-Dec Jan-Dec Sales excl. Tamiflu 257.4 375.3 68.6 -17.5 357.8 71.9 100.4 Oncology 100.1 140.2 71.4 -0.3 139.9 71.6
Slide 11: Impact from Foreign Exchange
vs. Forecast FY2010 3Q Financial Overview Impact from Foreign Exchange FX impacts on profits ( (vs. original i i l assumption) ti ) Original assumption for exchange rate (Billion JPY) Jan-Jun Jan-Sep CHF: 88.00JPY EUR: 130.00JPY Revised assumption for exchange rate -0.9 0.9 -1.8 1.8 CHF: 85.00JP
Slide 12: Overview of Development Pipeline
Overview of Development Pipeline CHUGAI PHARMACEUTICAL CO., LTD. Senior Vice President Head of Portfolio Management Unit Yutaka Tanaka October 22, 2010
Slide 13: Development Status - Oncology
Overview of Development Pipeline Development Status - Oncology In-house PA799 (overseas): solid tumors P1 started in Aug. In-house AF802: non-small cell lung cancer P1/2 started in Sep Sep. In- lilicensedd Xeloda: g gastric cancer Filed in Sep. • New Drug Application based on evidence in the public
Slide 14: Development Status - Bone & Joint, Others
Overview of Development Pipeline Development Status Status－ Bone & Joint, Joint Others In-house A t Actemra (overseas): ( ) sJIA JIA Filed in Oct. In- licensed RG1594 (ocrelizumab): RA Development discontinued • considering overall risk to benefit profile 3
Slide 15: AF802: Mode of Action (1)
Overview of Development Pipeline AF802:Mode of Action (1) Anaplastic Lymphoma Kinase (ALK) is a receptor tyrosine kinase which belongs to insulin receptor super-family Linkage between ALK signal derived from EML-ALK fusion protein and cancer growth has been suggested Approx. 5% of NSCLC patients
Slide 16: AF802: Mode of Action (2)
Overview of Development Pipeline AF802:Mode of Action (2) EML4-mediated homeostatic EML4 derived formation of gene di dimer ALK derived gene Activation Soda M. et al., Nature, 2007: 448, 561-6, Fig 1b partially modified 5
Slide 17: Contacts: Corporate Communications Dept.
Contacts: Corporate Communications Dept. Corporate Communications Group Tel: +81 (0)3-3273-0881 (0)3 3273 0881 Fax: +81 (0)3 (0)3-3281-6607 3281 6607 e-mail: pr@chugai-pharm.co.jp Masayuki Yamada, Shinichi Hirose, Hiroshi Araki, Kae Maeda Investor es o Relations ea o sG Group oup Tel: +81 (0)3-3273-
Chugai Pharmaceutical — Q3 2010 Earnings Presentation on 6ix